Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 901–1,000 of 1,020
Hanssen, N. M. J., & Jandeleit-Dahm, K. A. M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842339 · Cited by 40
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 41
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 41
“SAVOR-TIMI 53 assigned 16,492 patients with T2DM who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years [148] .”
BackgroundInfluentialZhou, Y., Zhang, Y., Zhang, R., Zhou, Y., Li, N., Wang, M., Tian, H., & Li, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001407 · Cited by 41
“Type 2 diabetes is among themost common non-communicable chronic diseases and is a major risk factor for cardiovascular disease.([10-14]) Since 2008, to ensure the cardiovascular safety of anti-diabetic agents for the treatment of type 2 diabetes, the Food and Drug Administration has required that new drugs show evide…”
BackgroundJung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy
Ma, L., Liu, D., Yu, Y., Li, Z., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587806 · Cited by 52
Yu, O. H. Y., Yin, H., & Azoulay, L. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.02.002 · Cited by 40
New Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 41
Type 2 Diabetes Medication Review
Sterrett, J., Bragg, S. W., & Weart, C. W. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.019 · Cited by 43
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 39
“51), without excess HF-related mortality (53).”
Zannad, F., Stough, W. G., Lipicky, R. J., Tamargo, J., Bakris, G. L., Borer, J. S., Alonso García, M. D. L. A., Hadjadj, S., Koenig, W., Kupfer, S., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw007 · Cited by 38
“Outcomes with Alogliptin (EXAMINE) produced consistent findings of no major harm but no cardiovascular benefit for these DPP-4 inhibitors.(5,6) In the Trial Evaluating Cardiovascular Out-”
BackgroundSelf-citationSchernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 40
One‐year efficacy and safety of saxagliptin add‐on in patients receiving dapagliflozin and metformin
Matthaei, S., Aggarwal, N., García-Hernández, P. A., Iqbal, N., Chen, H., JOHNSSON, E. K., Chin, A., & Hansen, L. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12741 · Cited by 39
“Prospective cardiovascular (CV) outcomes trials have also reported mixed findings as to whether DPP-4 inhibitors may increase the risk of hospitalization for heart failure in certain patients with pre-existing CV disease.(14,15) While additional CV outcomes trials for DPP-4 inhibitors are under way, it is recommended…”
Jax, T. W., Stirban, A. O., Terjung, A., Esmaeili, H. A., Berk, A., Thiemann, S., CHILTON, R. J., von Eynatten, M., & Marx, N. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0493-3 · Cited by 40
“In patients with advanced diabetes and at high cardiovascular risk, no change in the rates of cardiovascular outcomes was seen [8–10], although potential beneficial effects on the microvasculature such as reduced development and progression of microalbuminuria were reported [9].”
BackgroundDipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
Kim, N. H., Choi, J., Kim, N. H., Choi, K. M., Baik, S. H., Lee, J., & Kim, S. G. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.03.004 · Cited by 41
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 39
SAIS Study Group, Kitao, N., Miyoshi, H., Furumoto, T., Ono, K., Nomoto, H., Miya, A., Yamamoto, K., Inoue, A., Tsuchida, K., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0607-6 · Cited by 38
Hou, W., Chang, K., Li, C., & Ou, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13636 · Cited by 42
Ibrahim, A., Ghaleb, R., Mansour, H. M., Hanafy, A., Mahmoud, N. M., Elsharef, M. A., Salama, M. K., Elsaughier, S. M., Abdel-Wahid, L., Mohamed, M. E., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602251 · Cited by 45
Segar, M. W., Patel, K. V., Hellkamp, A. S., Vaduganathan, M., Lokhnygina, Y. V., Green, J. B., Wan, S., Kolkailah, A. A., Holman, R. R., Peterson, E. D., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024094 · Cited by 42
Self-citationEffects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
“RCT data on the risk of macro-and microvascular outcomes with DPP-4Is demonstrate a slightly protective effect [91–95].”
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 46
“Ten studies enrolled diabetic patients with a history of macrovascular disease [9, 10, 34–41], and HEART2D, EXAMIN, and DIGAMI1 only enrolled patients who had recently experienced adverse coronary events.”
BackgroundCardiac and Renovascular Complications in Type 2 Diabetes — Is There Hope?
Ingelfinger, J. R., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejme1607413 · Cited by 38
Gejl, M., Starup‐Linde, J., Thomsen, J. L. S., Gregersen, S., & Vestergaard, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.096 · Cited by 39
Kadowaki, T., Marubayashi, F., Yokota, S., Katoh, M., & Iijima, H. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032249 · Cited by 37
“Prior studies have examined the long-term safety of saxagliptin (SAVORTIM53) [24] and alogliptin (EXAMINE) [25] in patients with a high risk of CVD.”
BackgroundMetformin as firstline treatment for type 2 diabetes: are we sure?
Boussageon, R., Gueyffier, F., & Cornu, C. (2016) · BMJ · doi:10.1136/bmj.h6748 · Cited by 40
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 43
Treatment of diabetic kidney disease: current and future targets
Kim, M. K. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.219 · Cited by 39
“Numerous preclinical and clinical studies now support the notion that DPP-4 exerts a renoprotective effect [24,27-38]; the studies are summarized in Table 1.”
BackgroundResultImpaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus
Akoumianakis, I., & Antoniades, C. A. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7421 · Cited by 41
Kwon, C. S., Seoane-Vazquez, E. C., & Rodríguez-Monguió, R. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2860-0 · Cited by 39
“The sensitivity analyses also included a scenario in which there was no difference in cardiovascular event rates after 2 years from initiation of metformin+DPP-4i and metformin+SU [26, 27].”
BackgroundAroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 38
“007) in the SAVOR-TIMI trial [18] and alogliptin which showed a non-statistically significant risk for HHF in subjects with pre-existing HF in the EXAMINE trial [25].”
MethodType 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Hashikata, T., Yamaoka‐Tojo, M., Kakizaki, R., Nemoto, T., Fujiyoshi, K., Namba, S., Kitasato, L., Hashimoto, T., Kameda, R., Maekawa, E., et al. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0724-7 · Cited by 40
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
Asche, C. V., Hippler, S. E., & Eurich, D. T. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0117-7 · Cited by 36
“Second, the results of the recently published SAVOR trial actually observed a statistically significantly increased risk of congestive heart failure with the use of saxagliptin [25].”
ResultTricco, A. C., Antony, J., Khan, P. A., Ghassemi, M., Hamid, J. S., Ashoor, H. M., Blondal, E., Soobiah, C., Yu, C. H. Y., Hutton, B., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005752 · Cited by 39
“1 years follow-up, DPP-4 inhibition was not significantly different than placebo for ischaemic events, yet the risk of hospitalisation for heart failure was increased for saxagliptin versus placebo.(37) We were unable to include these trials in our systematic review as they did not include only patients with T2DM fail…”
BackgroundResultChang, Y., Chuang, L., Lin, J., Chen, S., Lai, M., & Chang, C. (2015) · Diabetic Medicine · doi:10.1111/dme.12800 · Cited by 37
Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus
Konya, H. (2015) · World Journal of Experimental Medicine · doi:10.5493/wjem.v5.i2.110 · Cited by 39
Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure
Koyani, C. N., Kolesnik, E., Wölkart, G., Shrestha, N., Scheruebel, S., Trummer, C., Zorn‐Pauly, K., Hammer, A., Lang, P., Reicher, H., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.021 · Cited by 37
Gallwitz, B. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 37
Bekki, M., Tahara, N., Tahara, A., Igata, S., Honda, A., Sugiyama, Y., Nakamura, T., Sun, J., Kumashiro, Y., Matsui, T., et al. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180515154555 · Cited by 39
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Almagthali, A., Alkhaldi, E. H., Alzahrani, A. S., Alghamdi, A. K., Alghamdi, W. Y., & Kabel, A. M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.012 · Cited by 41
Hasan, A. A., von Websky, K., Reichetzeder, C., Tsuprykov, O., Gaballa, M. M. S., Guo, J., Zeng, S., Delić, D., Tammen, H., Klein, T., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.010 · Cited by 38
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
Takeuchi, S., Kohno, T., Goda, A., Shiraishi, Y., Kawana, M., Saji, M., Nagatomo, Y., Nishihata, Y., Takei, M., Nakano, S., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13954 · Cited by 39
“and worsening of HF upon treatment of diabetes with pioglitazone(24) and saxagliptin.(25) Furthermore, in the context of multimorbidity, the complex interactions among diseases”
BackgroundGao, H. X., Regier, E. E., & Close, K. L. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12377 · Cited by 36
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 35
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 40
“Hazard ratio (95% CI) P DPP-4is Interventional studies (RCTs) Scirica et al., 2013 [86] SAVOR-TIMI 53 2.1 Saxagliptin 157/8280 (1.9) 141/8212 (1.7) 1.11 (0.88–1.39) 0.38 White et al., 2013 [85] EXAMINE 1.5 Alogliptin Non-fatal stroke 29/2701 (1.1) 32/2679 (1.2) 0.91 (0.55–1.50) 0.71 Greene et al.,…”
InfluentialTong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 40
“gliptin was non-inferior compared with placebo for the primary composite CV outcome, although an increase in hospitalization for heart failure was observed [100].”
BackgroundInfluentialBrenner, C., Kränkel, N., Kühlenthal, S., Israel, L., Remm, F., Fischer, C., Herbach, N., Speer, T., Grabmaier, U., Laskowski, A., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.016 · Cited by 39
“cardiovascular death, ischemic stroke or myocardial infarction [46,47] but showed hints that it might be associated with an increased risk for heart failure outcomes [48].”
BackgroundHirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors
Nakamura, Y., Hasegawa, H., Tsuji, M., Udaka, Y., Mihara, M., Shimizu, T., Inoue, M., Goto, Y., Gotoh, H., Inagaki, M., et al. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.840 · Cited by 41
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
Fei, Y., Tsoi, M. F., Kumana, C. R., Cheung, T. T., & Cheung, B. M. Y. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.039 · Cited by 37
Treatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 38
Hsu, P., Sung, S., Cheng, H., Shin, S.-J., Lin, K., Chong, K., Yen, F., Yu, B.-H., Huang, C.-T., & Hsu, C.-C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00040 · Cited by 37
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 37
Mechanick, J. I., Adams, S., Davidson, J. A., Fergus, I. V., Galindo, R. J., McKinney, K. H., Petak, S. M., Sadhu, A. R., Samson, S. L., Vedanthan, R., et al. (2019) · Endocrine Practice · doi:10.4158/ps-2019-0080 · Cited by 33
“Savor-Timi-53 (126,127) Saxagliptin 75 NR 3.”
BackgroundSelf-citationSciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 38
Khan, M. S., Solomon, N. C., DeVore, A. D., Sharma, A., Felker, G. M., Hernandez, A. F., Heidenreich, P. A., Matsouaka, R., Green, J. B., Butler, J., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.11.001 · Cited by 38
Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Ohm, B., Moneke, I., & Jungraithmayr, W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15967 · Cited by 36
“However, several large-scale randomized controlled trials have evaluated the clinical cardiovascular outcome of saxagliptin, alogliptin and sitagliptin treat-ment (SAVOR-TIMI 53, EXAMINE and TECOS trials) (Green et al., 2015; Scirica et al., 2013; White et al., 2013).”
BackgroundInfluentialEnzan, N., Matsushima, S., Kaku, H., Tohyama, T., Nagata, T., Ide, T., & Tsutsui, H. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.09.015 · Cited by 35
“The SAVORTIMI 53 trial showed that saxagliptin increased the risk of HF.(18) Subsequently, the EXAMINE trial for alogliptin,(19) TECOS trial for sitagliptin,(17) CARMELINA trial for linagliptin,(26) a randomized controlled trial for omarigliptin,(20) and a meta-analysis of vildagliptin(21) reported no significant effe…”
BackgroundInfluentialKunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 39
Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial
Leiter, L. A., Teoh, H., Mosenzon, O., Cahn, A., Hirshberg, B., Stahre, C., Hoekstra, J. B. L., Alvarsson, M., Im, K., Scirica, B. M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12582 · Cited by 35
“Although baseline characteristics of the placebo and saxagliptin arms were balanced [5], imbalances were noted when the participants were re-categorized according to whether they had experienced a cancer event or not during the study (Table 1).”
BackgroundSelf-citationDevin, J. K., Pretorius, M., Nian, H., Yu, C., Billings, F. T., & Brown, N. J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001075 · Cited by 36
“GLP-1(9-36), which promotes endothelium-dependent vasodilation independent of the GLP-1 receptor.”
BackgroundMethodInfluentialNutraceutical approaches to metabolic syndrome
Sirtori, C. R., Pavanello, C., Calabresi, L., & Ruscica, M. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1366042 · Cited by 39
“This new molecular target is correlated to the development of T2D; a number of pharmacological inhibitors have been developed and are currently being used [56].”
BackgroundArnold, S. V., Echouffo-Tcheugui, J. B., Lam, C. S. P., Inzucchi, S. E., Tang, F., McGuire, D. K., Goyal, A., Maddox, T. M., Sperling, L. S., Fonarow, G. C., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.05.016 · Cited by 39
Self-citationCampbell, P. T., Krim, S. R., & Ventura, H. O. (2015) · Cardiac failure review · doi:10.15420/cfr.2015.01.01.8 · Cited by 44
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“(ORIGIN, SAVOR, EXAMINE, ADVANCE, ACCORD [6-11]) have failed to decrease cardiovascular event rates.”
BackgroundInfluentialDavidson, J. A. (2013) · Endocrine Practice · doi:10.4158/ep12303.ra · Cited by 35
Self-citationLeibowitz, G., Cahn, A., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Wei, C., Jermendy, G., Sheu, W. H., Sendon, J. L., Im, K., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12445 · Cited by 37
“The design [17,18] and principal results of this study have been published previously [16].”
BackgroundResultSelf-citationManagement of Hyperglycemia in Diabetic Kidney Disease
Neumiller, J. J., & Hirsch, I. B. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.214 · Cited by 38
“Recent findings from a large cardiovascular outcomes study with saxagliptin indicated a higher risk of hospitalization for heart failure in patients receiving saxagliptin (40).”
ResultMoon, J.-Y., Woo, J. S., Seo, J.-W., Lee, A., Kim, D. J., Kim, Y., Kim, S.-Y., Lee, K. H., Lim, S., Cheng, X. W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150745 · Cited by 34
“The SAVOR-TIMI 53 trial was associated with a 27% increase in hospitalization (for heart failure) among diabetic patients who received saxagliptin compared with placebo [2].”
BackgroundMethodRobinson, E., Tate, M., Lockhart, S. M., McPeake, C., O’Neill, K. M., Edgar, K. S., Calderwood, D., Green, B. D., McDermott, B. J., & Grieve, D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0386-5 · Cited by 40
“Notably, the evident importance of GLP-1(9–36)-mediated actions (together with the known pleiotropic actions of GLP-1 signalling) may at least partly explain the apparently disappointing results of recent large-scale DPP-4 inhibitor trials which failed to demonstrate any significant benefits on cardiovascular outcomes…”
BackgroundResultDPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 37
“007) although no excess heart failure-related mortality was noticed [42].”
BackgroundNMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 37
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 37
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 36
“DPP-4 inhibitors have demonstrated their cardiovascular safety but have not demonstrated a significant reduction in MACE outcomes within the four CVOTs published to date, involving nearly 50,000 people with Diabetes.”
BackgroundInfluentialPatorno, E., Najafzadeh, M., Pawar, A., Franklin, J. M., Déruaz‐Luyet, A., Brodovicz, K. G., Ortiz, A. J. S., Bessette, L. G., Kulldorff, M., & Schneeweiß, S. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.103 · Cited by 35
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 37
“Increased hospitalization for heart failure with the DPP-4 inhibitor saxagliptin in the Savor-Timi 53 trial and a non-statistically significant increase in the same outcome in the EXAMINE study of alogliptin provided the original rationale for a potentially sizeable active comparator differential with liraglutide in L…”
BackgroundResultRoles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Cao, F., Wu, K., Zhu, Y., & Bao, Z.-W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731273 · Cited by 37
“In SAVOR-TIMI53, saxagliptin was associated with a 27% increased risk of heart failure hospitalization, particularly in the first 12 months (136); the complex mechanisms and potential effects for this have not been fully understood.”
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Saxagliptin: A Review in Type 2 Diabetes
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0473-z · Cited by 37
“The change in ACR was prespecified as a shift from a baseline category of\30 mg/g (normal), 30–300 mg/g (microalbuminuria), or[300 mg/g (macroalbuminuria) [36, 40].”
BackgroundMethodInfluentialIs HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
Bejan‐Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B. V., Audier, P., Brabant, Y., Gueyffier, F., & Boussageon, R. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.04.001 · Cited by 43
Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Forsmark, C. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.009 · Cited by 36
Ou, H., Chang, K., Li, C., & Wu, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13241 · Cited by 36
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 35
“The only large‐scale trial that demonstrated a modest benefit is the reduced progression of microalbuminuria seen in SAVOR‐TIMI 53 with saxagliptin.(78)”
BackgroundTate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…either saxagliptin or apogliptin had no significant effects on their primary composite end points of cardiovascular death, or non-fatal MI/stroke (Scirica et al., 2013; White et al., 2013), although it should be noted that SAVOR-TIMI 53 reported a 27% increase in hospitalization for heart…”
BackgroundTratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 40
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Raschi, E., Poluzzi, E., Koci, A., Antonazzo, I. C., Marchesini, G., & Ponti, F. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.006 · Cited by 33
“Recently, the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4-Is) has been questioned by the results of SAVOR-TIMI and EXAMINE trials, which raised the hypothesis that DPP4-Is may precipitate and/or exacerbate HF [3,4].”
ResultRisk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
Bergmark, B. A., Bhatt, D. L., Braunwald, E., Morrow, D. A., Steg, P. G., Gurmu, Y., Cahn, A., Mosenzon, O., Raz, I., Bohula, E., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1736 · Cited by 31
Self-citationPacker, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1185 · Cited by 35
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Spencer, N. Y., Yang, Z., Sullivan, J. C., Klein, T., & Stanton, R. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200249 · Cited by 35
Giugliano, D., Maiorino, M. I., Longo, M., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Endocrine · doi:10.1007/s12020-019-01931-y · Cited by 35
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Self-citation
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.